LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Inicio・Lista de Acciones・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Cerrado

SectorSalud

18.95 3.5

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

18.4

Máximo

18.99

Métricas clave
By Trading Economics
Ingresos	-297M -81M
Ventas	-259M 200M
P/B Media del Sector	109.111 61.417
BPA	1.67
Margen de beneficio	-40.687
Empleados	733
EBITDA	-275M -47M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+71.45% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-332M 2.5B
Apertura anterior	15.45
Cierre anterior	18.95

Noticias sobre sentimiento de mercado

By Acuity

50%

154 / 351 Clasificación en Healthcare

Apellis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

13 mar 2026, 19:08 UTC

Noticias de Eventos Importantes

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

13 mar 2026, 18:48 UTC

Ganancias

Principales Movimientos del Mercado

Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss

13 mar 2026, 17:10 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

13 mar 2026, 17:10 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: Central Bank Decisions -2-

13 mar 2026, 16:47 UTC

Noticias de Eventos Importantes

The Week in Oil: Hormuz Crisis Pushes Brent Above $100

13 mar 2026, 22:27 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13 mar 2026, 22:13 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13 mar 2026, 22:04 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13 mar 2026, 22:00 UTC

Adquisiciones, fusiones, absorciones

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

13 mar 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

13 mar 2026, 20:02 UTC

Charlas de Mercado

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13 mar 2026, 19:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13 mar 2026, 19:35 UTC

Noticias de Eventos Importantes

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

13 mar 2026, 19:00 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

13 mar 2026, 18:49 UTC

Noticias de Eventos Importantes

The Iran War Could Upend AI. Here's How. -- Barrons.com

13 mar 2026, 18:24 UTC

Noticias de Eventos Importantes

Impact of Middle East Conflict on TotalEnergies Activities

13 mar 2026, 18:00 UTC

Noticias de Eventos Importantes

Is War Good For the Economy? -- WSJ

13 mar 2026, 17:23 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises by 1 to 412 -- Market Talk

13 mar 2026, 16:46 UTC

Charlas de Mercado

Noticias de Eventos Importantes

European Indexes End Week Lower as Oil Takes Driving Seat -- Market Talk

13 mar 2026, 16:38 UTC

Noticias de Eventos Importantes

Higher Oil Prices Could Bring a Global Economic Shock. This Is the Number to Watch. -- Barrons.com

13 mar 2026, 16:34 UTC

Adquisiciones, fusiones, absorciones

EQT Says It Received Around CHF21 Bln in Total From Galderma Share Sales

13 mar 2026, 16:33 UTC

Adquisiciones, fusiones, absorciones

EQT Receives Proceeds of Around CHF1.3B From Sell-Down

13 mar 2026, 16:32 UTC

Adquisiciones, fusiones, absorciones

EQT Completes Exit From Galderma

13 mar 2026, 16:20 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

13 mar 2026, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

13 mar 2026, 16:15 UTC

Noticias de Eventos Importantes

Why Exxon and Energy Stocks Finally Started to Rise This Week as the Iran War Escalated -- Barrons.com

13 mar 2026, 16:11 UTC

Charlas de Mercado

Carney Tries to Put Dismal Canada Jobs Data in Context -- Market Talk

13 mar 2026, 16:00 UTC

Noticias de Eventos Importantes

Here's Where the U.S. Economy Is Most Vulnerable to Iran War -- WSJ

13 mar 2026, 15:48 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Turn Higher as Supply Worries Remain -- Market Talk

Comparación entre iguales

Cambio de precio

Apellis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

71.45% repunte

Estimación a 12 meses

Media 31.53 USD 71.45%

Máximo 48 USD

Mínimo 18 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Apellis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

16 ratings

Comprar

Mantener

Vender

De acuerdo con 16 analistas que ofrecen calificaciones bursátiles a para Apellis Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

154 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.